166 related articles for article (PubMed ID: 17034462)
1. Biologic agents in psoriasis.
Lee MR; Cooper AJ
Australas J Dermatol; 2006 Nov; 47(4):217-29; quiz 229-30. PubMed ID: 17034462
[TBL] [Abstract][Full Text] [Related]
2. [Biological response modifiers in the treatment of immunoinflammatory diseases].
Skov L; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292
[TBL] [Abstract][Full Text] [Related]
3. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
Sobell JM; Kalb RE; Weinberg JM
J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
[TBL] [Abstract][Full Text] [Related]
4. [Biologic therapy and psoriasis].
Gamo R; López-Estebaranz JL
Actas Dermosifiliogr; 2006; 97(1):1-17. PubMed ID: 16540046
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Tutrone WD
Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins.
Lee SJ; Chinen J; Kavanaugh A
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S314-23. PubMed ID: 20036416
[TBL] [Abstract][Full Text] [Related]
7. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
Sauder DN; Mamelak AJ
J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
[TBL] [Abstract][Full Text] [Related]
8. [Biotechnological pharmaceuticals and their potential use in inflammatory skin diseases].
Villadsen L; Baadsgaard O
Ugeskr Laeger; 2000 Dec; 162(50):6820-4. PubMed ID: 11187134
[TBL] [Abstract][Full Text] [Related]
9. Duration of remission of biologic agents for chronic plaque psoriasis.
Langley RG; Gordon KB
J Drugs Dermatol; 2007 Dec; 6(12):1205-12. PubMed ID: 18189060
[TBL] [Abstract][Full Text] [Related]
10. Redefining clinical response in psoriasis: targeting the pathological basis of disease.
Ortonne JP
J Drugs Dermatol; 2004; 3(1):13-20. PubMed ID: 14964742
[TBL] [Abstract][Full Text] [Related]
11. [Biological dermatologic agents. The Danish Society of Dermatology].
Iversen L; Kragballe K;
Ugeskr Laeger; 2007 Mar; 169(12):1100. PubMed ID: 17394811
[No Abstract] [Full Text] [Related]
12. Briakinumab.
Lima XT; Abuabara K; Kimball AB; Lima HC
Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
[TBL] [Abstract][Full Text] [Related]
13. Biologicals dramatic advances in the treatment of psoriasis.
Wilsmann-Theis D; Martin S; Reber M; Kwiek B; Bieber T; Novak N
Curr Pharm Des; 2006; 12(8):989-99. PubMed ID: 16533166
[TBL] [Abstract][Full Text] [Related]
14. Treatment of inflammatory dermatoses with novel biologic agents: a primer.
Nussbaum R; Krueger JG
Adv Dermatol; 2002; 18():45-89. PubMed ID: 12528402
[No Abstract] [Full Text] [Related]
15. What have we learned in dermatology from the biologic therapies?
Nickoloff BJ; Stevens SR
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S143-51. PubMed ID: 16488330
[TBL] [Abstract][Full Text] [Related]
16. Immunopathogenesis of psoriasis.
Lee MR; Cooper AJ
Australas J Dermatol; 2006 Aug; 47(3):151-9. PubMed ID: 16866993
[TBL] [Abstract][Full Text] [Related]
17. Recombinantly engineered human proteins: transforming the treatment of psoriasis.
Gottlieb AB; Bos JD
Clin Immunol; 2002 Nov; 105(2):105-16. PubMed ID: 12482385
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis: a fresh look.
Galadari I; Sharif MO; Galadari H
Clin Dermatol; 2005; 23(5):491-502. PubMed ID: 16179183
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
20. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
